LANTHEUS HOLDINGS INC (LNTH)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for LNTH
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| LNTH | Member; Director | 61 | ["Audit Committee Financial Expert", "financial sophistication", "Extensive biotechnology expertise across finance, strategic planning, operations and transactions", "Current President and CEO, Zentalis Corporation", "Former CEO, Harpoon Therapeutics (November 2021 until March 2024)", "Former Chief Financial and Business Officer, Rainier Therapeutics, Inc. (2018 to 2020)", "Former Chief Business Officer and Chief Financial Officer, Cascadian Therapeutics, Inc. (September 2010 until March 2018)", "Former CFO and Vice President of Finance, VLST Corporation (January 2006 until September 2010)", "Former Vice President of Strategic Planning, Dendreon Corporation (October 2000 until October 2005)", "Former Controller, Amgen (March 1996 to April 1998)", "Current Director, Zentalis Corporation", "Current Director, Member of Audit and Compensation Committees, Seismic Therapeutic (since September 2024)", "Prior Director and Chair of Audit Committee, Dynavax Technologies Corporation (July 2020 until May 2025)", "Prior Director (October 2018 until March 2024) and Chair of Audit Committee (from 2018 until 2021), Harpoon Therapeutics", "Prior Director, Graybug Vision (September 2020 until March 2023)", "B.S., Finance, Colorado State University", "MBA, Heriot-Watt University of the Edinburgh University in Scotland"] | ["Member", "Audit Committee", "Talent and Compensation Committee"] | 2026 |
Biography sourced from the proxy statement filing.
Julie Eastland Director since 2024 Independent 61 years old Committees: Audit Committee Talent and Compensation Committee Specific Expertise: Ms. Eastland was chosen as a Director because of her extensive biotechnology expertise across finance, strategic planning, operations and transactions. Career Highlights: Current President and CEO, Zentalis Corporation Former CEO, Harpoon Therapeutics (November 2021 until March 2024) Former Chief Financial and Business Officer, Rainier Therapeutics, Inc. (2018 to 2020) Former Chief Business Officer and Chief Financial Officer, Cascadian Therapeutics, Inc. (September 2010 until March 2018) Former CFO and Vice President of Finance, VLST Corporation (January 2006 until September 2010) Former Vice President of Strategic Planning, Dendreon Corporation (October 2000 until October 2005) Former Controller, Amgen (March 1996 to April 1998) Other Boards: Current Director, Zentalis Corporation Director, Member of Audit and Compensation Committees, Seismic Therapeutic (since September 2024) Prior Director and Chair of Audit Committee, Dynavax Technologies Corporation (July 2020 until May 2025) Director (October 2018 until March 2024) and Chair of Audit Committee (from 2018 until 2021), Harpoon Therapeutics Director, Graybug Vision (September 2020 until March 2023) Education: B.S., Finance, Colorado State University MBA, Heriot-Watt University of the Edinburgh University in Scotland